Payments by company
Table 2 presents the distribution of payments and amounts by the top 10
companies. Of the 84 companies contributing payments, the foremost 10
and 20 companies, by total payment magnitude, were responsible for
64.6% ($28.0 million) and 83.8% ($36.4 million) of all payments
within the 2016 to 2020 timeframe. AstraZeneca made the largest total
payments amounting to 14.0% of all payments ($6.1 million) in monetary
value, followed by Boehringer Ingelheim Japan ($4.1 million, 9.4%),
Novartis Pharma ($3.2 million, 7.4%), Kyorin Pharmaceutical ($2.6
million, 6.0%), and Mitsubishi Tanabe Pharma ($2.4 million, 5.6%).
Regarding the number of allergists receiving payments, Kyorin
Pharmaceutical was at the forefront, providing payments to 994
allergists (25.2% of all allergists), with AstraZeneca following
closely at 884 allergists (22.4%), and Novartis Pharma at 799
allergists (20.3%), over the span of five years.